Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response

Journal of Experimental Medicine

Volumn 200, Issue 10, 2004, Pages 1243-1256

  Jones, Nicola A ^a   Wei, Xiping ^b   Flower, Darren R ^a   Wong, MaiLee ^a   Michor, Franziska ^e   Saag, Michael S ^c,d   Hahn, Beatrice H ^c,d   Nowak, Martin A ^e   Shaw, George M ^b,c,d   Borrow, Persephone ^a  

^a EDWARD JENNER INST FOR VACC RES   (United Kingdom)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d University of Alabama at Birmingham   (United States)

^e HARVARD UNIVERSITY   (United States)

Author keywords

Antigenic variation; Biological models; Cellular immunity; HIV 1; Viremia

Indexed keywords

CD8 ANTIGEN; COMPLEMENTARY DNA; CYTOKINE; EPITOPE; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 160; MAJOR HISTOCOMPATIBILITY ANTIGEN; SYNTHETIC PEPTIDE; TRANSACTIVATOR PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VIRUS RNA;

ANTIGENICITY; ARTICLE; BIOLOGICAL MODEL; CASE REPORT; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UNINDEXED SEQUENCE; VIREMIA; VIRUS INFECTION; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; CHROMIUM RADIOISOTOPES; DNA PRIMERS; EPITOPES, T-LYMPHOCYTE; GENES, GAG; GENES, TAT; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON TYPE II; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 9244254245     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20040511     Document Type: Article

References (46)

1. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103-6110.
2. Koup, R.A., J.T. Safrit, Y. Cao, C.A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D.D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
3. McMichael, A.J., and S.L. Rowland-Jones. 2001. Cellular immune responses to HIV. Nature. 410:980-987.
4. McMichael, A., and T. Hanke. 2002. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Nat. Rev. Immunol. 2:283-291.
5. Barouch, D.H., and N.L. Letvin. 2002. Viral evolution and challenges in the development of HIV vaccines. Vaccine. 20:A66-A68.
6. O'Connor, D.H., T.M. Allen, and D.I. Watkins. 2002. Cytotoxic T-lymphocyte escape monitoring in simian immunodeficiency virus vaccine challenge studies. DNA Cell Biol. 21:659-664.
7. Borrow, P., H. Lewicki, X. Wei, M.S. Horwitz, N. Peffer, H. Meyers, J.A. Nelson, J.E. Gairin, B.H. Hahn, M.B.A. Oldstone, and G.M. Shaw. 1997. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3:205-211.
8. Geels, M.J., M. Cornelissen, H. Schuitemaker, K. Anderson, D. Kwa, J. Maas, J.T. Dekker, E. Baan, F. Zorgdrager, R. van den Burg, et al. 2003. Identification of sequential viral escape mutants associated with altered T cell responses in a human immunodeficiency virus type 1-infected individual. J. Virol. 77:12430-12440.
9. O'Connor, D.H., T.M. Allen, T.U. Vogel, P. Jing, I.P. DeSouza, E.L. Dodds, E.J. Dunphy, C. Melsaether, B. Mothe, H. Yamamoto, et al. 2002. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat. Med. 8:493-499.
10. Mellors, J.W., C.R. Rinaldo Jr., P. Gupta, R.M. White, J.A. Todd, and L.A. Kingsley. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272:1167-1170.
11. Clark, S.J., M.S. Saag, W.D. Decker, S. Campbell-Hill, J.L. Roberson, P.J. Veldkamp, J.C. Kappes, B.H. Hahn, and G.M. Shaw. 1991. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N. Engl. J. Med. 324:954-960.
12. Graziosi, C., G. Pantaleo, L. Butini, J.F. Demarest, M.S. Saag, G.M. Shaw, and A.S. Fauci. 1993. Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA. 90:6405-6409.
13. Piatak, M.J., M.S. Saag, L.C. Yang, S.J. Clark, J.C. Kappes, K.-C. Luk, B.H. Hahn, G.M. Shaw, and J.D. Lifson. 1993. High levels of HIV-1 in plasma during all stages of infection detennined by competitive PCR. Science. 259:1749-1754.
14. + memory T cells. J. Exp. Med. 186:859-865.
15. Nolan, G.P., S. Fiering, J.F. Nicolas, and L.A. Herzenberg. 1988. Fluorescence-activated cell analysis and sorting of viable mammalian cells based on beta-D-galactosidase activity after transduction of Escherichia coli lacZ. Proc. Natl. Acad. Sci. USA. 85:2603-2607.
16. Addo, M.M., X.G. Yu, A. Rathod, D.I. Cohen, R.L. Eldridge, D. Strick, M.N. Johnstone, C. Corcoran, A.G. Wurcel, C.A. Fitzpatrick, et al. 2003. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 77:2081-2092.
17. Wei, X., S.K. Ghosh, M.E. Taylor, V.A. Johnson, E.A. Emini, P. Deutsch, J.D. Lifson, S. Bonhoeffer, M.A. Nowak, B.H. Hahn, et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 373:117-122.
18. Draenert, R., S. Le Gall, K.J. Pfafferott, A.J. Leslie, P. Chetty, C. Brander, E.C. Holmes, S.C. Chang, M.E. Feeney, M.M. Addo, et al. 2004. Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J. Exp. Med. 199:905-915.
19. Wei, X., J.M. Decker, S. Wang, H. Hui, J.C. Kappes, X. Wu, J.F. Salazar-Gonzalez, M.G. Salazar, J.M. Kilby, M.S. Saag, et al. 2003. Antibody neutralization and escape by HIV-1. Nature. 422:307-312.
20. Yang, O.O., P.T.N. Sarkis, A.K. Trocha, S.A. Kalams, R.P. Johnson, and B.D. Walker. 2003. Impacts of avidity and specificity on the antiviral efficacy of HIV-1-specific CTL. J. Immunol. 171:3718-3724.
21. HIV Sequence Compendium. 2003. C.L. Kuika, B. Foley, E. Freed, B. Hahn, B. Korber, P.A. Marx, F. McCutcher, J.W. Mellors, and S. Wolinsky, eds. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
22. Wagner, R., B. Leschonsky, E. Harrer, C. Paulus, C. Weber, B.D. Walker, S. Buchbinder, H. Wolf, J.R. Kalden, and T. Harrer. 1999. Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized from a long-term nonprogressor: constraints on immune escape associated with targeting a sequence essential for viral replication. J. Immunol. 162:3727-3734.
23. Richman, D.D., T. Wrin, S.J. Little, and C.J. Petropoulos. 2003. Rapid evolution of the neutralizing antibody response in HIV type 1 infection. Proc. Natl. Acad. Sci. USA. 100:4144-4149.
24. Nowak, M.A., and R.M. May. 2000. Virus dynamics. Oxford University Press, Oxford, UK. 237 pp.
25. Mansky, L.M., and H.M. Temin. 1995. Lower in vivo mutation rate of human immunodeficiency virus-type 1 than that predicted from the fidelity of reverse transcriptase. J. Virol. 69:5087-5094.
26. Markowitz, M., M. Louie, A. Hurley, E. Sun, M. DiMascio, A.S. Perelson, and D.D. Ho. 2003. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J. Virol. 77:5037-5038.
27. Klenerman, P., R.E. Phillips, C.R. Rinaldo, L.M. Wahl, G. Ogg, R.M. May, A.J. McMichael, and M.A. Nowak. 1996. Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection. Proc. Natl. Acad. Sci. USA. 93:15323-15328.
28. Goh, W.C., M.E. Rogel, C.M. Kinsey, S.F. Michael, P.N. Fultz, M.A. Nowak, B.H. Hahn, and M. Emerman. 1998. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat. Med. 4:65-71.
29. Allen, T.M., D.H. O'Connor, P. Jing, J.L. Dzuris, B.R. Mothe, T.U. Vogel, E. Dunphy, M.E. Liebl, C. Emerson, N. Wilson, et al. 2000. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature. 407:386-390.
30. Stittelaar, K.J., R.A. Gruters, M. Schutten, C.A. van Baalen, G. van Amerongen, M. Cranage, P. Liljestrom, G. Sutter, and A.D. Osterhaus. 2002. Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. Vaccine. 20:2921-2927.
31. Baalen, C.A., C. Guillon, M.M. Baalen, E.J. Verschuren, P.H. Boers, A.D. Osterhaus, and R.A. Gruters. 2002. Impact of antigen expression kinetics on the effectiveness of HIV-specific cytotoxic T lymphocytes. Eur. J. Immunol. 32:2644-2652.
32. Richman, D.D. 2001. HIV chemotherapy. Nature. 410:995-1001.
33. + T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75:11983-11991.
34. + T cells in primary HIV-1 infection. J. Virol. 77:6867-6878.
35. + T cells with a predominant Vβ usage during the primary immune response to HIV. Nature. 370:463-467.
36. Pantaleo, G., J.F. Demarest, T. Schacker, M. Vaccarezza, O.J. Cohen, M. Daucher, C. Graziosi, S.S. Schnittman, T.C. Quinn, G.M. Shaw, et al. 1997. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc. Natl. Acad. Sci. USA. 94:254-258.
37. Kelleher, A.D., C. Long, E.C. Holmes, R.L. Allen, J. Wilson, C. Conlon, C. Workman, S. Shaunak, K. Olson, P. Goulder, et al. 2001. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J. Exp. Med. 193:375-386.
38. Borrow, P., and G.M. Shaw. 1998. Cytotoxic T-lymphocyte escape viral variants: how important are they in viral evasion of immune clearance in vivo? Immunol. Rev. 164:37-51.
39. Selier, P., B.M. Senn, P. Klenerman, U. Kalinke, H. Hengartner, and R.M. Zinkernagel. 2000. Additive effect of neutralizing antibody and antiviral drug treatment in preventing virus escape and persistence. J. Virol. 74:5896-5901.
40. + T cell responses with efficient natural control of primary HIV-1 infection. AIDS. 18:749-755.
41. Moore, C.B., M. John, I.R. James, F.T. Christiansen, C.S. Witt, and S.A. Mallal. 2002. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science. 296:1439-1443.
42. Yusim, K., C. Kesmir, B. Gaschen, M.M. Addo, M. Altfeld, S. Brunak, A. Chigaev, V. Detours, and B.T. Korber. 2002. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion of HIV-1 global variation. J. Virol. 76:8757-8768.
43. Mortara, L., F. Letourneur, H. Gras-Masse, A. Venet, J.-G. Guillet, and I. Bourgault-Villada. 1998. Selection of virus variants and emergence of virus escape muatants after immunization with an epitope vaccine. J. Virol. 72:1403-1410.
44. Barouch, D.H., J. Kunstman, M.J. Kuroda, J.E. Schmitz, S. Santra, F.W. Peyerl, G.R. Krivulka, K. Beaudry, M.A. Lifton, D.A. Gorgone, et al. 2002. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature. 415:335-339.
45. Allen, T.M., L. Mortara, B.R. Mothe, M. Liebl, P. Jing, B. Calore, M. Piekarczyk, R. Ruddersdorf, D.H. O'Connor, X. Wang, et al. 2002. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J. Virol. 76:4108-4112.
46. HIV Molecular Immunology. 2003. B.T.M. Korber, C. Brander, B.F. Haynes, R. Koup, C. Kuika, J.P. Moore, B.D. Walker, and D.I. Watkins, eds. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.